INTRODUCTION
The calcium-activated Ser/Thr phosphatase calcineurin regulates gene expression in lymphocytes and other cell types by activating transcription factors such as calcineurin-dependent transcription factors nuclear factor of activated T cells (NFATc) [1] . The immunosuppressants cyclosporin A (CsA) and FK506 associate with endogenous immunophilins [2] , and the resulting complexes inhibit calcineurin and prevent T cell receptor (TCR)-induced activation of lymphocytes [3] . CsA and FK506 are used to treat autoimmune disorders and transplant rejection. However, prolonged treatment with these compounds, particularly CsA, causes severe side effects such as nephrotoxicity and hypertension. As CsA and FK506 also inhibit the immunophilins to which they bind, it is unclear whether these side effects owe to sustained calcineurin inhibition or are mediated by calcineurin-independent mechanisms [4] . CsA-induced nephrotoxicity has been linked to the accumulation of transforming growth factor-␤1 (TGF-␤1) in kidney [5, 6] . CsA has been shown to induce TGF-␤1 production in kidney cell lines [7] and to activate its promoter in A549 lung carcinoma cells [8] . In T cells, CsA was shown to enhance TGF-␤1 mRNA accumulation and protein production in cells stimulated with anti-CD3 antibodies or pharmacological activators of protein kinase C (PKC) and calcium mobilization [9] . These observations suggested that CsA might act as a general inducer of TGF-␤1 in different cell types, raising the question of whether calcineurin, the main target of CsA, is involved in TGF-␤1 expression.
TGF-␤1 is a key immunoregulatory cytokine that plays a pivotal role in immune homeostasis and prevents spontaneous autoimmunity [10] . TGF-␤1 is also produced by infiltrating leukocytes at sites of inflammation, as shown during allograft rejection [11] and experimental autoimmune encephalomyelitis [12] . TGF-␤1 counteracts the deleterious immune response and has been associated with remission in rodent models of multiple sclerosis and parasite-induced colitis [12, 13] . Virtually all T cells, naïve or T helper (Th)0, Th1, Th2, and Th3 clones, are competent to express TGF-␤1 [14] . However, spe-cialized T cell subsets, such as CD4ϩ/CD25ϩ, T regulatory, and Th3 cells, produce mainly TGF-␤1 and IL-10 rather than prototypical Th1/Th2 cytokines [15] [16] [17] . TGF-␤1 is synthesized and secreted as a latent precursor, which is held in an inactive conformation by its own amino-terminal propeptide, the latency-associated protein (LAP). The mature, bioactive carboxy-terminal TGF-␤1 dimer is released by conformational modifications of LAP through proteolysis or other mechanisms [18] , occurring, for instance, during apoptosis, where bioactive TGF-␤1 is released by apoptotic cells from preformed intracellular stores [19] .
Here, we have studied the regulation of TGF-␤1 biosynthesis by CsA and FK506 in response to TCR stimulation and autocrine TGF-␤1 induction. We show that concentrations of immunosuppressants (100 nM-1 M), which are effective in suppressing TCR-induced production of interleukin (IL)-2, do not have a substantial effect on TGF-␤1 biosynthesis in activated, normal lymphocytes. However, pretreatment of fresh T cells with CsA and FK506 during primary TCR stimulation decreased their production of TGF-␤1 during secondary stimulation. Finally, higher concentrations of CsA (10 M), but not of FK506, promote the release of preformed TGF-␤1, independent of de novo synthesis, by inducing apoptosis. Our results show that the activation requirements for the induction of TGF-␤1 and its sensitivity to CsA may vary depending on the cell type and CsA concentrations and highlight a greater heterogeneity in the response of TGF-␤1 to CsA than previously realized in earlier studies.
MATERIALS AND METHODS

Reagents
CsA, FK506, phorbol 12-myristate 13-acetate (PMA), and the calcium ionophore ionomycin were from Calbiochem (Darmstadt, Germany). The caspase inhibitor Z-Val-Ala Asp-(Ome; z-VAD)-fluoromethylketone was from Enzyme Systems Products (Livermore, CA).
Cell culture and cytokine enzyme-linked immunosorbent assay (ELISA)
Culture medium was high-glucose Dulbecco's modified Eagle's medium (DMEM; 41965-039, Gibco, Pasley, UK), supplemented with L-Glut (2 mM), 2-mercaptoethanol (50 M), and sodium pyruvate (1 mM; all supplements from Gibco). The human T cell line Jurkat [Clone E6-1, American Type Culture Collection (ATCC), Manassas, VA, #TIB 152], kindly provided by Jeremy Luban (Columbia University College of Physicians and Surgeons, New York, NY), and the human lung carcinoma cell line A549 (ATCC #CCL-185) were grown in the above culture medium plus 10% heat-inactivated fetal calf serum (FCS; Linus, Cultek, Spain). Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats of healthy volunteers by gradient sedimentation with Lymphoprep TM (Axis-Shield, Oslo, Norway). PBMC (2ϫ10 6 cells/ml) were stimulated for 3 days with 2.5 g/ml phytohemagglutinin (PHA-L; Sigma-Aldrich, Steinheim, Germany) and 5.5 ng/ml IL-2 (Eurocetus, Amsterdam, the Netherlands) in culture medium plus 10% heatinactivated FCS. After 3 days, cultures were washed, and cells were adjusted at 2 ϫ 10 6 cells/ml in medium plus 10% FCS and 5.5 ng/ml IL-2. Cultures were used 24 or 48 h later and contained Ն97% T cells by flow cytometry with anti-CD3 (SpvT3b) [20] . Cells (2ϫ10 6 cells/ml, 1 ml) were stimulated in 48-well plates with mouse anti-human CD3 (SpvT3b, 2 g/well) bound to wells coated with rabbit anti-mouse immunoglobulin G (10 g/well, Sigma-Aldrich), plus mouse anti-human CD28 (CD28.2 NA/LE, BD Biosciences, San Diego, CA) added in solution (1 g/ml). Cells (2ϫ10 6 cells/ml) were stimulated without IL-2 in medium with 2% FCS to reduce the background of bovine TGF-␤1 from serum, as the ELISA used (TGF-␤1 Emax Immunoassay, Promega, Madison, WI) also detects bovine TGF-␤1. Hepes buffer (50 mM, pH 7.4) was added to the medium to maintain a constant pH and prevent spurious activation of TGF-␤1 by acidification of supernatants during culture. Bioactive TGF-␤1 in supernatants was measured directly, and total TGF-␤1 (latent plus bioactive) was quantitated after acid-activation following the manufacturer's instructions. Intracellular TGF-␤1 was measured in postnuclear supernatants of cells washed twice with phosphate-buffered saline (PBS) and lysed (3ϫ10 6 cells/ml) in PBS with 1% Nonidet P-40 (NP-40) and protease inhibitors (leupeptin, antipain, chemostatin, and pepstatin, all at 2 g/ml). NP-40 (1%) did not affect the measurement of control samples and TGF-␤1 standards. IL-2 ELISA (OptEIA human IL-2 set) was from BD Biosciences. The neutralizing anti-human TGF-␤ receptor II antibody (AF-241-NA) was from R&D Systems (Minneapolis, MN).
Northern blot
Total RNA isolated using a guanidium isothiocyanate-based method (Trizol, Invitrogen, Pasley, UK) was resolved in 1% agarose formaldehyde gels, transferred to Nytran membranes (Schleicher and Schuell, Dassel, Germany), UV-cross-linked, and hybridized with a TGF-␤1 probe comprising from ϩ348 to ϩ653 in the coding sequence of human TGF-␤1 cDNA. The TGF-␤1 cDNA (IMAGE Clone 3510592, GenBank Accession BE312000) was from the I.M.A.G.E. consortium (UK HGMP Resource Center, Cambridge). Probe labeling, hybridization, and chemiluminescence were performed with a nonisotopic method (North2South direct labeling and detection kit, Pierce, Rockford, IL). The signal-to-background ratio in gels and films was measured using the Bio-Rad Gel Doc 2000 imaging system and the Quantity One 4.3.1 Bio-Rad (Hercules, CA) software.
Reporter assays
The human TGF-␤1 promoter construct TG5-Luc [21] was made by subcloning a HincII-KpnI fragment (-453 to ϩ11) from phTG2-CAT [21] into pXP2 [22] . The entire promoter region was sequenced and confirmed to be free of mutations. The NFATc-responsive reporter pIL-13/Luc [23, 24] and expression vectors encoding the calcineurin B subunit [25] , the NFATc-inhibitory peptide VIVIT [26] , and the NFAT5 inhibitory dimerization domain (DD5) [27] -the latter two as fusions with the enhanced green fluorescent protein (EGFP)-were kindly provided by Anjana Rao (Center for Blood Research, Boston, MA) and Cristina López-Rodríguez (Center for Genomic Regulation, Barcelona, Spain). Wild-type calcineurin and the CsA-insensitive mutant V314R constructs in pBJ5 [28] were kindly provided by Joseph Heitman (Duke University Medical Center and Howard Hughes Medical Institute, Durham, NC). TKRenilla (Promega) was used for normalization. The plasmid pEGFP.N1 was from BD Biosciences. Jurkat T cells (20ϫ10 6 cells/400 l in DMEM) were mixed with plasmid DNA (luciferase reporters, 1 g/10 6 cells; TK-Renilla, 0.2 g/10 6 cells; and expression vectors, 0.5-1 g/10 6 cells) and electroporated in a Bio-Rad gene pulser (260 V, 950 F). A549 cells (10ϫ10 6 cells/400 l in DMEM) were electroporated (260 V, 950 F) with luciferase reporters (2 g/10 6 cells) and TK-Renilla (0.5 g/10 6 cells). Electroporated cells were washed in medium to remove dead cells and allowed to recover for 24 h before stimulation. Luciferase activity was measured with the dual luciferase reporter system (Promega) in a Berthold FB12 luminometer (Pforzheim, Germany).
Apoptosis and flow cytometry
Human lymphocytes (PHA blasts) or Jurkat cells (2ϫ10 6 cells/ml) were treated with CsA or FK506, as indicated in the respective figure legends. Cells were stained with annexin-V-Fluos (Roche, Indianapolis, IN; 1/1000 dilution) in annexin-V buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM KCl, 1.36 mM CaCl 2 , 1 mM MgCl 2 ) at 4°C for 20 min and washed to remove unbound annexin-V. Propidium iodide (PI; 2.5 g/ml) was added 10 min before analysis by two-color flow cytometry (FACScan, BD Biosciences).
Statistical analysis
Mean and SD were calculated from at least three independently performed experiments unless otherwise indicated in figure legends. Statistical significance (P value) was determined by the ANOVA test (post-hoc analysis using the Tukey algorithm).
RESULTS
Regulation of the TGF-␤1 promoter in Jurkat T cells and A549 lung carcinoma cells in response to calcineurin activation and the calcineurin inhibitors CsA and FK506
In view of an earlier work describing the activation of the TGF-␤1 promoter by CsA in the human lung carcinoma cell line A549 [8] , we asked whether a similar response occurred in Jurkat T cells and compared the regulation of the TGF-␤1 promoter in both cell lines. In Jurkat cells, the TGF-␤1 promoter was activated by the combination of the phorbol ester PMA and the calcium ionophore ionomycin but not by each individual stimulus (Fig. 1A) . CsA and FK506 inhibited the stimulation by PMA plus ionomycin. These activation requirements were similar to that of the calcineurin and NFATcdependent IL-13 promoter [23] , suggesting that activation of the TGF-␤1 promoter in Jurkat T cells involved calcineurin. This was confirmed by transfecting cells with the CsA-insensitive calcineurin mutant V314R [28] . Activation of the TGF-␤1 promoter was specifically resistant to CsA in cells expressing the V314R mutant but not in cells transfected with wild-type calcineurin (Fig. 1B , left panel). FK506 inhibited the reporter in all cases. Activation of the promoter was repressed by 57% by the NFATc-inhibitory peptide VIVIT [26] but not by the NFAT5-specific inhibitor DD5 [27] (Fig. 1B , right panel). These results indicated that the TGF-␤1 promoter could be activated by calcineurin-dependent NFATc transcription factors in Jurkat T cells. However, in A549 cells, PMA alone activated the TGF-␤1 promoter without requiring costimulation with ionomycin ( Fig. 1C , left panel). CsA and FK506 (both at 100 nM) did not repress the promoter but did not activate it either, in contrast with a previous report in which the TGF-␤1 promoter was activated by CsA in A549 cells [8] . We confirmed that A549 cells responded to CsA and FK506 by testing that the NFATc-dependent IL-13 promoter was activated by the combination of PMA and ionomycin and inhibited by CsA and FK506 (Fig. 1C, right panel) . However, differences between our results in A549 cells and those reported by Prashar et al. [8] 10 years ago might be attributed to the possibility that despite very similar culture conditions, this tumor cell line may display functional variations over the time in different laboratories. Nonetheless, our results indicated that calcineurin-dependent and independent pathways in different cell types can activate the TGF-␤1 promoter when stimulated with the same reagents and that CsA and FK506 might not be general activators of TGF-␤1 transcription.
Production of TGF-␤1 by normal human T cells in response to TCR stimulation and the immunosuppressants CsA and FK506
In view of the differences in the regulation of the TGF-␤1 promoter in Jurkat and A549 cells, we analyzed the regulation of TGF-␤1 in normal human T cells (PHA blasts) stimulated with anti-CD3 alone or with anti-CD3 antibody plus anti-CD28 antibody (hereafter referred to as anti-CD3/CD28) in the absence or presence of CsA or FK506. As shown in Figure 2 (upper panels), 24 h stimulation with anti-CD3/CD28 induced the production of TGF-␤1, mostly in its latent form. Stimulation with anti-CD3 alone induced almost maximal TGF-␤1 production, in contrast with IL-2, which required costimulation with anti-CD28 (Fig. 2, lower panel) . CsA or FK506, at 100 nM, did not substantially affect the production of TGF-␤1 by CD3 and CD3/CD28 but effectively suppressed IL-2 production in the same cells (Fig. 3A, lower panel) .
In addition to TCR activation, TGF-␤1 can be induced by autocrine stimulation of its own receptor. We assessed the contribution of this pathway by incubating T lymphocytes with a neutralizing anti-TGF-␤ receptor II antibody. As shown in Figure 3 , blockade of the TGF-␤ receptor suppressed the basal TGF-␤1 production and partially inhibited the induction by anti-CD3/CD28 (30.5Ϯ12.7% inhibition), indicating that basal TGF-␤1 production in T cells was mainly autocrine, whereas only a small proportion of TGF-␤1 induced by TCR stimulation depended on the autocrine pathway. Neither CsA nor FK506 altered the basal autocrine production of TGF-␤1. However, FK506, but not CsA, attenuated the inhibition by anti-TGF-␤ receptor antibody in CD3/CD28-stimulated cells (from 30.5Ϯ12.7% to 7.8Ϯ4%), indicating that although these drugs did not affect autocrine TGF-␤1 synthesis, FK506 could modestly enhance TGF-␤1 production induced by CD3/CD28 if the autocrine loop was blocked. Blockade of the TGF-␤ receptor caused a small induction of IL-2 in unstimulated cells, which was insensitive to CsA and FK506, and it boosted the levels of IL-2 induced by CD3/CD28 costimulation. Neutralization of the TGF-␤ receptor rendered IL-2 production by CD3/CD28 partially resistant to CsA and FK506. This result indicated that the low levels of bioactive TGF-␤1 produced by T cells are biologically relevant to sustain its own autocrine stimulation, down-regulate IL-2 production, and enhance the immunosuppressive effect of CsA and FK506.
Although in Jurkat T cells, the TGF-␤1 promoter was activated by calcineurin, the relative insensitivity of TGF-␤1 to CsA and FK506 in nontransformed lymphocytes suggested that calcineurin may not be a major regulator of this cytokine in normal T cells. The TCR activates PKC and calcineurin pathways, which can be activated with the PKC activator PMA and ionomycin, respectively. We analyzed the production of TGF-␤1 by lymphocytes activated with PMA (10 nM), ionomycin (0.3 M), or their combination in the absence or presence of CsA (1 M) and measured the amount of TGF-␤1 accumulated in the supernatants as well as the intracellular content of the cytokine in 1% NP-40 lysates of the same cells (Fig. 4, A and B) . As shown in Figure 4A , PMA effectively induced the production of TGF-␤1, whereas ionomycin alone did not and even inhibited by 30% the induction by PMA. However, CsA did not cause significant variations in the pro- duction of TGF-␤1 by cells treated with PMA, ionomycin, or both, indicating that CsA did not affect pathways activated by those stimuli. As shown in Figure 4B , the levels of intracellular TGF-␤1 were not affected by PMA, ionomycin, or CsA, added individually or in combination. These results indicated that PMA enhanced the overall synthesis of the cytokine. Consistent with this, PMA increased the levels of TGF-␤1 mRNA (5.6-fold) after 5 h stimulation (Fig. 4C) . In the same experiment, secreted TGF-␤1 was detected later (24 h) in the supernatants. TGF-␤1 mRNA and protein levels in CsA-and FK506-treated cells displayed little variation with respect to untreated controls. We confirmed that 100 nM FK506 substantially prevented the activation of calcineurin, as shown by the inhibition of the calcineurin-dependent dephosphorylation of NFATc2/NFAT1 in PHA blasts (Supplementary Fig. 1 ).
Our previous experiments were done in preactivated lymphocytes. We asked whether TGF-␤1 was regulated in a similar manner in fresh T cells during primary and secondary stimulation. Fresh PMBC were stimulated with or without CsA or FK506 as shown in the diagram in Figure 5A . Primary stimulation with anti-CD3/CD28 induced a progressive production of TGF-␤1 that was not inhibited by CsA (500 nM) or FK506 (100 nM; Fig. 5B , upper panels). Secondary stimulation with anti-CD3/CD28 elicited a stronger TGF-␤1 production than that of primary stimulation, which was also insensitive to CsA but slightly enhanced (21%) by FK506. However, induction of TGF-␤1 during secondary stimulation was decreased by 28% when cells had been continuously treated with CsA or FK506 during 5 days. In contrast with TGF-␤1, both drugs remarkably inhibited IL-2 (Fig. 2B, lower panels) . IL-2 production during primary stimulation with anti-CD3/CD28 was maximal at 24 h, declining sharply at 70 h, and was inhibited by 67%, although not completely blunted by CsA and FK506. This observation agrees with earlier papers, showing that CD28 costimulation confers IL-2 production by fresh T cells a relative resistance to CsA [29] . With regard to secondary TCR stimulation, production of IL-2 was of greater magnitude than in the primary stimulation but was almost completely suppressed (98%) by CsA or FK506. Cells that had been pretreated with the immunosuppressants during primary stimulation produced IL-2 poorly (6Ϯ16% of nonpretreated cultures) during secondary stimulation, even when the drugs were removed, and were further inhibited by freshly added CsA or FK506. These results support the conclusion that sustained treatment of T cells with CsA or FK506 does not enhance TGF-␤1 but can moderately decrease its production during Altogether, our experiments indicated that CsA and FK506 concentrations, which effectively inhibited IL-2 production by fresh and preactivated T lymphocytes, did not substantially modify their ability to produce TGF-␤1 in response to CD3, CD3 plus CD28 costimulation, or an autocrine pathway. Indeed, although CsA and FK506 do not induce the synthesis of TGF-␤1 in T cells, they sharply skew the TGF-␤1/IL-2 ratio toward TGF-␤1, simply by inhibiting IL-2 production.
Induction of apoptosis and release of bioactive TGF-␤1 by CsA and not FK506 in human T cells
Our experiments showed so far that the production of TGF-␤1 was largely insensitive to immunosuppressive doses of CsA and FK506, and we wondered whether these compounds would perform differently at higher concentrations. Whereas lower concentrations of CsA and FK506 (100 nM) did not induce the production of total or bioactive TGF-␤1 by T cells (Fig. 2) , 10 M CsA caused the accumulation of bioactive TGF-␤1 in the supernatant after 24 h, as shown in Figure 6A . A lower CsA concentration (1 M) had no effect and neither did FK506 at 1 and 10 M. Visual examination of the cultures suggested that CsA was toxic to cells. Flow cytometry analysis using annexin-V and PI staining confirmed that CsA caused substantial cell death at 24 h (Fig. 6B) . CsA toxicity was not prevented by a neutralizing anti-TGF-␤ receptor antibody, indicating that TGF-␤1 release was the result, rather than the cause, of cell death (Fig. 6C) . Similar results were obtained with Jurkat cells (Fig. 6D) . CsA-induced apoptosis was detected at early timepoints, as shown by the presence of annexin-V ϩ /PI -cells between 3 and 6 h of CsA treatment (Fig. 7A) . Cells died progressively (9 h onwards), as revealed by positive staining with PI. Cells treated with 10 M FK506 did not undergo apoptosis in the same period. The results above indicated that CsA might cause the release of TGF-␤1 by inducing apoptosis. Consistent with this hypothesis, the general caspase inhibitor z-VAD prevented apoptosis and the release of TGF-␤1 in Jurkat cells exposed to 10 M CsA during 7 h (Fig. 5B, upper and lower panels). Finally, inhibitors of transcription (actinomycin D) and protein synthesis (cycloheximide) did not affect the release of TGF-␤1 by apoptotic Jurkat T cells, indicating that CsA induced the release of TGF-␤1 from preformed stores and not by de novo synthesis (Fig. 7C ).
DISCUSSION
Earlier reports described that CsA activated the TGF-␤1 promoter in A549 cells and increased its mRNA levels in lymphocytes, cell lines, and kidney in mice [7, 8] . These observations lent support to the notion that CsA might contribute to nephrotoxicity by inducing TGF-␤1 biosynthesis. Inhibition of calcineurin is a major mechanism underlying the immunosuppressive effect of CsA. Calcineurin is also inhibited by FK506, for which conflicting results had been reported regarding its ability to induce TGF-␤1 [30, 31] . In this context, it was unclear whether TGF-␤1 can be regulated by calcineurin.
We have analyzed the production of TGF-␤1 in response to calcineurin activation and the immunosuppressants CsA and FK506 in normal human T lymphocytes and cell lines, assessing different parameters relevant to TGF-␤1 regulation. Our work has yielded three main results: The TGF-␤1 promoter can be activated by calcineurin and NFATc and inhibited by CsA and FK506 in Jurkat T cells but was insensitive to the immunosuppressants in A549 cells; the independent induction of PBMC isolated from buffy coats were separated in three groups and stimulated at 3 ϫ 10 6 cells/ml with anti-CD3/CD28 during 70 h in the absence (No inhibitor) or presence of 100 nM CsA or 100 nM FK506. After primary stimulation, cells were washed, adjusted to 2 ϫ 10 6 cells/ml, and cultured in medium with IL-2 (5.5 ng/ml) but without anti-CD3/CD28 and cultured for another 48 h. Cells that had been pretreated with CsA or FK506 during primary stimulation were maintained with their respective immunosuppressant freshly added. Forty-eight hours later, cells from the three groups were washed, adjusted to 2 ϫ 10 6 cells/ml, and restimulated during 24 h with anti-CD3/ CD28 in the absence or presence of CsA or FK506 as indicated. Cells were maintained in medium with 2% FCS throughout the entire experiment. (B) Samples were collected at 24 and 70 h during primary stimulation and at 24 h during secondary stimulation. TGF-␤1 (total) and IL-2 were quantified by ELISA. Mean Ϯ SD of three independent cultures is shown. Induction of TGF-␤1 by anti-CD3/CD8 during primary stimulation was statistically significant (*, PϽ0.01, nϭ3), whereas neither CsA nor FK506 had a significant effect at 24 or 70 h. In the secondary stimulation, FK506 enhanced the production of TGF-␤1 by anti-CD3/CD28 (*, PϽ0.05, nϭ3). Cells that had been pretreated with CsA or FK506 during the primary stimulation produced less TGF-␤1 than the untreated group during the secondary stimulation (**, PϽ0.01, nϭ3).
TGF-␤1 by TCR stimulation or an autocrine pathway in normal T cells is largely unaffected, neither induced nor repressed, by CsA and FK506 at doses (Յ1 M), which effectively suppress the induction of IL-2, and this result supports the conclusion that the calcineurin inhibitors CsA and FK506 might not be general inducers of TGF-␤1 biosynthesis; and high concentrations of CsA (10 M) cause the release of bioactive TGF-␤1 from preformed intracellular stores by inducing apoptosis in T cells. FK506 at 10 M induced neither, indicating that downregulation of calcineurin-dependent functions might not be sufficient to cause some of the CsA toxic effects. Our results provide an alternative angle to the long-held view that CsA is a general inducer of TGF-␤1 and suggest that the response of TGF-␤1 to CsA and FK506 in different cell types might be more heterogeneous than realized previously.
The regulation of the TGF-␤1 promoter in Jurkat cells hints at the possibility that calcineurin might activate TGF-␤1 in some cells. This is supported by a recent article describing that induction of diabetes with streptozotocin (STZ) in rats upregulated calcineurin, activated NFATc1/2, and increased the expression of TGF-␤1 in glomeruli, tubule, and cortex [32] . Induction of TGF-␤1 mRNA by STZ in mesangial cells was inhibited by CsA, whereas in cortex, it was up-regulated by CsA. In view of these observations and our results, it seems plausible that calcineurin and NFATc signaling could have different effects on TGF-␤1 expression depending on the cell type. In this regard, other cytokines such as lymphotoxins (LT) require calcineurin activation in some cell types but not in others: LT␣ is inhibited by CsA in T cells but not in B cells [33] , whereas LT␤ is CsA-sensitive in the T cell lines MOLT4 and Jurkat but not in normal T lymphocytes [26, 33] .
Production of TGF-␤1 induced via TCR or the TGF-␤ receptor in preactivated T cells (PHA blasts) was largely insensitive to CsA and FK506 concentrations (100 nM), which suppressed TCR-induced production of IL-2 by more than 98%. Unlike IL-2, induction of TGF-␤1 did not require CD28 costimulation, and TGF-␤1 induced by anti-CD3 alone was again insensitive to CsA and FK506. However, fresh T cells that had been pretreated with CsA or FK506 during 5 days produced almost 30% less TGF-␤1 during secondary stimulation with anti-CD3/CD28. Still, this inhibition was not enhanced by the addition of fresh CsA or FK506 and was in sharp contrast with the much higher sensitivity of IL-2 to these immunosuppressants. Conversely, FK506, but not CsA, enhanced the CD3/CD28-induced production of TGF-␤1 by T cells in two types of experiments: when TGF-␤ receptors were blocked (Fig. 3) and during secondary TCR stimulation of PBMC (Fig. 5) . However, these increases were of low magnitude, were not observed with CsA, and did not correlate with the relative inhibition of IL-2 by CsA or FK506. We thus propose that substantial down-regulation of calcineurin pathways by CsA and FK506, to the extent of suppressing the production of IL-2 in normal T cells, may have little effect on TGF-␤1. Independent experiments in cells stimulated with phorbol ester and calcium ionomycin showed that PMA (10 nM) alone induced the production of TGF-␤1 by T cells. Induction was 30% lower in cells costimulated with PMA and ionomycin, suggesting that calcium mobilization and perhaps calcineurin activation might reduce the stimulatory effect of other pathways. However, it is unclear whether this inhibitory effect of ionomycin represents that physiological activation of calcineurin would partially repress TGF-␤1 induction, as CsA did not enhance the production of TGF-␤1 induced by PMA or PMA plus ionomycin, and neither CsA nor FK506 enhanced TGF-␤1 induction with anti-CD3/CD28, which also mobilizes calcium and activates calcineurin.
To a certain extent, our results are in contrast with earlier papers regarding the effect of CsA on TGF-␤1 synthesis in T cells. Preceding studies had shown that CsA (100 nM-2 M) moderately enhanced (Յ twofold) the production of TGF-␤1 in lymphocytes only when cells were stimulated with anti-CD3 antibodies or mitogens but not in cells treated with CsA alone [9, 34] . More recently, other authors have found no effect of CsA on TGF-␤1 in T cells [35] . These studies had not included FK506. Our analysis indicates that the production of TGF-␤1 induced by the TCR or by TGF-␤1 itself in normal human T cells is quite insensitive to immunosuppressive doses of CsA and FK506 and might suggest that lymphocytes reacting to an allograft in CsA or FK506-treated transplant subjects may produce TGF-␤1 as a result of their activation by alloantigens, without requiring further stimulation from CsA or FK506. This view is supported by studies showing that TGF-␤1 was upregulated in transplanted hearts in rats during immune-mediated rejection, acute (without CsA) or chronic (with CsA), but not in control hearts of CsA-treated animals [11] . An independent study also showed that the increase of TGF-␤1 induced during rejection of heart allografts in rats was neither enhanced nor repressed by CsA or FK506 [36] . In the same line, it has been shown that TGF-␤1 accumulation in kidney during rejection in rats correlates with the number and activation state of infiltrating lymphocytes [37] .
We have found that CsA induced the release of bioactive TGF-␤1 in lymphocytes as result of cell death and independently of de novo synthesis. These effects required high doses of CsA (10 M), in contrast with the protective effect of submicromolar concentrations of CsA in preventing TCR-induced cell death [38] . Our results suggest that CsA-induced apoptosis might contribute to regulate TGF-␤1 in experimental models of toxicity that use high doses of the drug. Nephrotoxicity protocols in rats and mice use high CsA doses (15-80 mg CsA/kg body weight) [7] , and CsA levels in blood can reach 5.16 g/ml (4.3 M) after 28 days in rats injected with CsA 15 mg/kg/day [39] . Our titration experiments indicated that CsA could still induce detectable apoptosis in T cells and A549 cells at concentrations of 5 M (not shown). In human patients, CsA levels in blood oscillate from 0.2 to 0.4 M during immunosuppressive regimes and can attain peak values of 1.6 -2 M [40] . These concentrations are clearly lower than those measured in models of CsA nephrotoxicity in rodents, raising the question of whether the effects seen in experimentation animals accurately reproduce the situation in humans. In this regard, recent work has concluded that neither latent nor bioactive TGF-␤1 is increased in serum and plasma of CsA or FK506-treated patients, suggesting that these drugs do not trigger an overall increase in TGF-␤1 levels [41] . However, kidney biopsies of CsA-but not FK506-treated patients showed localized accumulation of bioactive TGF-␤1 without increasing the latent cytokine [42] . Processing of latent TGF-␤1 to its bioactive form occurs during apoptosis in different cell types [19] . Although T cells undergo apoptosis under high concentrations of CsA, other cell types such as myoblasts, endothelial cells, and kidney tubular cells die with lower doses (100 nM-1 M) in the range measured in blood in human patients [43] [44] [45] . In this regard, it might be possible that CsA could cause the release of TGF-␤1 by inducing apoptosis of sensitive cells. This mechanism does not exclude the previous view that CsA may enhance TGF-␤1 synthesis. Indeed, both effects might combine, as TGF-␤1 locally released from apoptotic cells may induce its own production in other cells via paracrine stimulation.
Our finding that 10 M FK506 did not cause apoptosis nor release of TGF-␤1 in T cells suggests that calcineurin inhibition may not suffice to explain CsA-induced cell death. Disruption of cyclophilins might underlie CsA toxicity, as CsA analogs (MeVal-4-CsA and MeIle-4-CsA), which do not inhibit calcineurin but block cyclophilin activity, induce apoptosis in endothelial cells comparably with CsA [43] . A recent article shows that transgenic mice that overexpress cyclophilin A are resistant to CsA-induced nephrotoxicity, and mice expressing a dominant-negative cyclophilin A mutant have exacerbated nephrotoxicity [46] . As CsA requires cyclophilins to inhibit calcineurin, one would reason that CsA should inhibit calcineurin more efficiently in the cyclophilin A transgenic. The fact that these animals present less renal damage and survived longer than nontransgenic controls indicates that mechanisms other than calcineurin inhibition are important in CsA toxicity in vivo.
